Commentary: Is neoadjuvant chemoimmunotherapy for esophageal cancer the next great frontier?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Commentary: Is neoadjuvant chemoimmunotherapy for esophageal cancer the next great frontier?

Published:2024-08 Issue:2 Volume:168 Page:429-430
ISSN:0022-5223
Container-title:The Journal of Thoracic and Cardiovascular Surgery
language:en
Short-container-title:The Journal of Thoracic and Cardiovascular Surgery

Author:

Lee Rachel M.,Antonoff Mara B.^ORCID

Publisher

Elsevier BV

Reference9 articles.

1. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma;Yu;J Thorac Cardiovasc Surg,2024

2. Preoperative chemoradiotherapy for esophageal or junctional cancer;van Hagen;N Engl J Med,2012

3. Esophageal cancer: an updated surveillance epidemiology and end results database analysis;Then;World J Oncol,2020

4. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021

5. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis;Ge;JAMA Netw Open,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3